Drug Index


Mechanism :

Adenosine is an endogenous nucleoside occurring in all cells of the body. It
slows conduction time through the A-V node, and can interrupt the re-entry pathways through the A-V node, therefore can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT), including PSVT associated with Wolff-Parkinson-White Syndrome.

Indication :

  • PSVT to convert to sinus rhythm, including those associated with accessory bypass tracts WPW syndrome.
  • Diagnostic to elucidate mechanism of tachycardia.

Contraindications :

Second- or third-degree A-V block.

Sinus node disease, such as sick sinus syndrome or symptomatic bradycardia.

Known hypersensitivity to adenosine.

Dosing :

Children with a Body Weight <50 kg
Initial dose: 0.05 to 0.1 mg/kg as a rapid IV bolus given either centrally or peripherally.
Repeat administration: If conversion of PSVT does not occur within 1-2 minutes, additional bolus injections of adenosine can be administered at incrementally higher doses, increasing the amount given by 0.05 to 0.1 mg/kg. Follow each bolus with a saline flush. This process should continue until sinus rhythm is established. (Cumulative dose of 12 mg should not be exceeded).
Children with a Body Weight >50 kg
Initial dose: 6 mg given as a rapid intravenous bolus (administered over a 1-2 second period).
Repeat administration: If the first dose does not result in elimination of the supraventricular tachycardia within 1-2 minutes, 12 mg should be given as a rapid intravenous bolus. This 12 mg dose may be repeated a second time if required.
Max dose: 12 mg/dose or cumulative dose of 30 mg.
For diagnostic test for tachycardia:
0.1 mg/kg IV followed by 0.2 mg/kg IV given with a rapid IV push over 1-3 seconds.
Maximum dose: 6 mg initial dose.

Adverse Effect :

Transient chest pain, bradycardia, dyspnoea, diaphoresis, facial flushing, headache, nervousness, numbness, paraesthesia, bronchospasm, chest pain, hemolytic anemia, choking, tingling in arms and light headedness.

Interaction :

Dipyridamole: Enhanced effect, reduce dose of adenosine.
Theophylline/xanthines: Antagonise action.
Caffeine: May diminish the therapeutic effect of Adenosine.
Carbamazepine: May enhance the adverse/toxic effect of Adenosine. Specifically, the risk of higher degree heart block may be increased. Management: Consider using a lower initial dose of adenosine in patients who are receiving carbamazepine.
Digoxin: May enhance the adverse/toxic effect of Adenosine.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function
10-20Dose as in normal renal function
<10Dose as in normal renal function

Dose in Patients undergoing Renal Replacement Therapies
CAPDNot dialysed. Dose as in normal renal function
HDNot dialysed. Dose as in normal renal function
HDF/High fluxUnknown dialysability. Dose as in normal renal function
CAV/VVHDNot dialysed. Dose as in normal renal function

Hepatic Dose :

No dosage adjustments are recommended.
03/23/2024 04:35:19 Adenosine
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0